newsfilter
← Earnings
Earnings Releases·

Tvardi Therapeutics — Third Quarter 2026 Earnings Summary

Tvardi Therapeutics reported a net loss of $6.1 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its TTI-101 program. The company plans to advance its lead candidate TTI-109 into clinical trials for ulcerative colitis in 2027, pending Investigational New Drug clearance and additional funding. TTI-101 is currently being evaluated in a Phase 1b/2 study for hepatocellular carcinoma, with topline data expected in the early first quarter of 2027. As of September 30, 2026, Tvardi held $22.3 million in cash and cash equivalents, which is projected to fund operations through the third quarter of 2027.

Company
TVARDI THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology